Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

48269

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions officials in his Department have had with the National Institute for Health and Care Excellence (NICE) on the development of NICE's highly specialised technologies programme since 1 January 2014; what the content of those discussions was; and if he will make a statement.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	196411
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>Departmental officials have had no such discussions. Officials may discuss individual highly specialised technology topics with the National Institute for Health and Care Excellence, including at the topic selection stage.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

48276

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 24 March 2014, Official Report, column 120W, on haemolytic uraemic syndrome, what discussions NHS England has had with the National Institute for Health and Care Excellence (NICE) since 1 January 2014 on NICE's appraisal of eculizumab; and if he will make a statement.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	196426
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>We understand that NHS England was formally consulted on the scope of the National Institute for Health and Care Excellence's (NICE) evaluation of eculizumab for atypical haemolytic uraemic syndrome. NHS England was also consulted on the evaluation consultation document, which was published on 27 February.</p><p> </p><p>Following the publication of NICE's draft guidance on eculizumab, NICE sought further advice from NHS England on what considerations relating to the management of its specialised commissioning budget it considers should be taken into account in formulating a recommendation. The response from NHS England will be considered by NICE at the next meeting of the evaluation committee.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

48280

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 31 March 2014, Official Report, column 491W, on medical treatments, what technology appraisals were conducted by the National Institute for Health and Care Excellence in the last five years; what the most plausible cost per quality adjusted life-year for each such appraisal was; what the estimated eligible patient population was for each appraised indication; on which appraisals end-of-life criteria were applied in each final appraisal determination; and on which date each such appraisal was (a) initiated and (b) concluded.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	196429
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>National Institute for Health and Care Excellence (NICE) technology appraisal decisions published between 2000 to end of February 2014 have already been placed in the Library.</p><p> </p><p>NICE has advised that it does hold the most plausible cost per quality adjusted life-year for each technology appraisal, the estimated patient population for each appraised indication, details of appraisals where the end-of-life criteria were applied in each final appraisal determination and the dates each appraisal was initiated and concluded. However, this information could only be provided at disproportionate cost.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

48281

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will discuss with the National Institute for Health and Care Excellence (NICE) ensuring that assessments of treatments by NICE conducted through (a) normal technology appraisals and (b) highly specialised technology appraisals is consistent in its (i) engagement with stakeholders and (ii) wider methodological approaches.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	196428
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>We have no plans to do so. As an independent body, the National Institute for Health and Care Excellence is responsible for developing its methods and processes and applying them consistently.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

48282

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how the National Institute for Health and Care Excellence (NICE) assesses the cost-effectiveness of an intervention when the data available are uncertain; what assessment NICE has made of the average range around the most-plausible cost-per-QALY in its technology appraisals; and if he will make a statement.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	196424
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) follows a rigorous process in the appraisal of technologies to ensure that judgements regarding the cost-effective use of NHS resources are consistently applied. This includes consideration of the uncertainty generated where available data have serious limitations.</p><p> </p><p>When making judgements on cost effectiveness, the NICE appraisal committee will consider a number of factors including the strength of the clinical-effectiveness evidence, the innovative nature of the technology, the robustness and plausibility of the economic models, the degree of certainty around the incremental cost-effectiveness ratio (ICER), the range and plausibility of the ICERs and the likelihood of decision error and its consequences. Full details of how the Committee takes uncertainty into account is contained within sections 5.8, 6.3 and 6.4 of NICE's Guide to the Methods of Technology Appraisal 2013, which is available at:</p><p>http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9</p><p> </p><p>NICE advises that it has not carried out an assessment of the average range around the most plausible cost-per Quality Adjusted Life Year (QALY) in its technology appraisals. We understand that although NICE usually specifies the most plausible cost-per-QALY for each technology appraisal, it does not normally specify a range for this assessment.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

48283

	registered interest
	date	10/04/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 24 March 2014, Official Report, column 120W, on haemolytic uraemic syndrome, for what reasons it was felt that further advice was needed on the overall cost implications, benefits and affordability of eculizumab; when it was first concluded that such further advice was needed; for what reasons the seeking of that advice was delayed until the National Institute for Health and Care Excellence took on responsibility for assessing highly specialised technologies; and if he will make a statement.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	196427
	answer	answer is ministerial correction date of answer 06/05/2014 answer text <p>Ministers concluded that further advice was needed on the overall cost implications, benefits and affordability of eculizumab as, while Advisory Group for National Specialised Services (AGNSS) members were convinced of the clinical effectiveness of the drug, they noted the very high costs of the drug and the increasing cost profile for the National Health Service.</p><p> </p><p>AGNSS was informed of this decision on 17 January 2013. On 7 February 2013, the Department conveyed its decision to the National Institute for Health and Care Excellence (NICE) so that NICE could begin preparatory work in advance of taking on formal responsibility for evaluating highly specialised technologies on 1 April 2013.</p><p> </p><p>While NICE carries out its evaluation, the current interim commissioning arrangements by NHS England in line with the ‘Clinical Commissioning Policy Statement: Eculizumab for atypical haemolytic uraemic syndrome' will remain in place. The policy statement is available at:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/09/e03-hss-a.pdf</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 06/05/2014 12:00:00 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

58532

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what resources his Department has allocated to help carers of dementia patients.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	199341
	answer	answer is ministerial correction date of answer 12/06/2014 answer text <p>Carers are central to the Government's reform of social care and support, with significant improvements in the Care Act which extends carers' rights to an assessment which will be based on the appearance of a need for support. For the first time, local authorities will be required to meet carers' eligible needs for support. The Act also creates a new statutory principle to promote an individual's well-being, including health and emotional well-being, which will apply equally to carers.</p><p> </p><p>We have provided £400 million to the National Health Service over four years from 2011 for carers to have breaks from their caring responsibilities. In the 2013 Spending Review, we announced the £3.8 billion Better Care Fund, which includes £130 million funding for carers' breaks for 2015-16.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 12/06/2014 15:10:38 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

58533

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to improve standards of NHS care for dementia sufferers.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	199335
	answer	answer is ministerial correction date of answer 12/06/2014 answer text <p>NHS England has an ambition that two thirds of the estimated number of people with dementia should have a diagnosis and access to post diagnostic support by March 2015. We are informed by NHS England that there is a tremendous amount of work being undertaken by clinical commissioning groups (CCGs) across the country to improve diagnosis rates and quality of care for people with dementia. NHS England has found wide variation; with some CCGs having a longer journey to achieve the ambition than others. NHS England is providing a package of support to help CCGs to improve timely diagnosis and post-diagnosis support for people with dementia.</p><p> </p><p>In addition, the Government's refreshed Mandate to Health Education England, published on 1 May 2014, stated that a further 250,000 NHS staff will receive Tier 1 training on dementia by March 2015, in addition to the 100,000 NHS staff who received Tier 1 training in 2013-14.</p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 12/06/2014 15:27:15 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

58534

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many local authorities have signed up to become dementia friendly since the launch of the Dementia Challenge; and what other progress has been made since that date.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	199337
	answer	answer is ministerial correction date of answer 12/06/2014 answer text <p>The dementia friendly communities recognition process was launched by Alzheimer's Society in September 2013 and 55 communities have already signed up. We have therefore increased our original ambition of 20 communities committed to work to become dementia friendly, as set out in the Prime Minister's Challenge on Dementia, to reach 75 communities by March 2015. In addition, 59 local authorities are members of local Dementia Action Alliances.</p><p> </p><p>The Department has worked with Alzheimer's Society to develop the recognition process for dementia friendly communities. Malpas has signed up to the recognition process and is receiving support in its work to become dementia friendly. The Department is also working with Alzheimer's Society and the British Standards Institute to develop a code of practice for dementia friendly communities, which will help communities to continue in their work to become dementia friendly.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 199338 question first answered 12/06/2014 14:34:01 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien

58535

	registered interest
	date	05/06/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to help Malpas to develop a dementia friendly community.
	tabling member constituency	Eddisbury
	tabling member printed	Mr Stephen O'Brien
	uin	199338
	answer	answer is ministerial correction date of answer 12/06/2014 answer text <p>The dementia friendly communities recognition process was launched by Alzheimer's Society in September 2013 and 55 communities have already signed up. We have therefore increased our original ambition of 20 communities committed to work to become dementia friendly, as set out in the Prime Minister's Challenge on Dementia, to reach 75 communities by March 2015. In addition, 59 local authorities are members of local Dementia Action Alliances.</p><p> </p><p>The Department has worked with Alzheimer's Society to develop the recognition process for dementia friendly communities. Malpas has signed up to the recognition process and is receiving support in its work to become dementia friendly. The Department is also working with Alzheimer's Society and the British Standards Institute to develop a code of practice for dementia friendly communities, which will help communities to continue in their work to become dementia friendly.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 199337 question first answered 12/06/2014 14:34:02 answering member 1439 label Biography information for Norman Lamb
	tabling member	427 label Biography information for Mr Stephen O'Brien